Endo Acquires Paladin for $1.6B in Stock, Cash
By Catherine Shaffer
Tuesday, November 5, 2013
Shares of Paladin Labs Inc. soared 49.4 percent Tuesday on news of an acquisition by Endo Health Solutions for $1.6 billion in stock and cash. The merger will marry Paladin’s pipeline of products in attention deficit hyperactivity disorder, pain, urology and allergy with Endo’s health care assets under a newly formed entity based in Ireland, led by Endo’s management team.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.